FDA Calls Vets and Drug Makers to Animal Fee Renewal Talks
Published Date: 5/11/2026
Notice
Summary
The FDA is inviting vets, animal drug makers, and animal lovers to join meetings about renewing the Animal Drug User Fee Act before it expires in 2028. These meetings, starting June 2026 and happening every four months, will help decide how fees for animal drug reviews are set and used. If you want to have a say, let the FDA know by June 1, 2026!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
ADUFA Authority Ends September 30, 2028
The current Animal Drug User Fee Act authority (ADUFA V) expires September 30, 2028. The notice states that without new legislation to reauthorize the program, FDA will no longer be able to collect user fees for future fiscal years to fund the new animal drug review process.
Stakeholder Sign‑up Deadline: June 1, 2026
If you represent a stakeholder group (veterinary professionals, patient and consumer advocacy groups, or scientific and academic experts) and want to join FDA’s ADUFA reauthorization discussions, notify FDA by email at [email protected] by June 1, 2026. Stakeholders who notify will be included in future stakeholder discussions while FDA negotiates with the regulated industry.
Scheduled Consultation Meetings Starting June 2026
FDA will hold stakeholder consultation meetings beginning in June 2026 and will continue meeting at least once every 4 months during ADUFA reauthorization negotiations. Meetings will be held in person at the FDA Harvey W. Wiley Federal Building, 5001 Campus Drive, College Park, MD 20740, and virtually via Microsoft Teams.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-09281, Submission for OMB Review; Comment Request
The Department of Agriculture is asking for public feedback on a plan to improve markets for American farmers by making it easier to sell their products directly and build stronger local food networks. This update aims to boost farming communities and streamline how information is collected, with comments due by June 10, 2026. Farmers, co-ops, and anyone involved in agriculture will feel the positive changes, with no new costs announced yet.
Next: 2026-09284, Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Generic Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate
The FDA is gearing up to renew the Animal Generic Drug User Fee Act (AGDUFA) before it expires in September 2028. They’re inviting vets, scientists, and animal drug makers to join regular meetings starting June 2026 to help shape the next phase. This means ongoing teamwork and funding to keep affordable animal medicines coming!